135
Views
8
CrossRef citations to date
0
Altmetric
Original Research

Value For Money In The Treatment Of Patients With Type 2 Diabetes Mellitus: Assessing The Long-Term Cost-Effectiveness Of IDegLira Versus iGlarLixi In Italy

, , ORCID Icon, , & ORCID Icon
Pages 605-614 | Published online: 07 Oct 2019

Figures & data

Table 1 Treatment Effects Applied In The Analysis

Figure 1 Cumulative Incidence Of Diabetes-Related Complications.

Abbreviations: BDR, background diabetic retinopathy; CHF, congestive heart failure; ESRD, end-stage renal disease; GRP, gross proteinuria; MA, microalbuminuria ME, macular edema; MI, myocardial infarction; PDR, proliferative diabetic retinopathy; PVD, peripheral vascular disease; Rec., recurring; SVL, severe vision loss.
Figure 1 Cumulative Incidence Of Diabetes-Related Complications.

Table 2 Long-Term Cost-Effectiveness Outcomes

Figure 2 Results of deterministic sensitivity analyses.

Abbreviations: BMI, body mass index; CI, confidence interval; EUR, 2017 Euros; HbA1c, glycated hemoglobin; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; SMBG, self-monitoring of blood glucose; UKPDS, United Kingdom Prospective Diabetes Study; WTP, willingness-to-pay.
Figure 2 Results of deterministic sensitivity analyses.

Figure 3 Cost-effectiveness acceptability curve.

Abbreviations: EUR, 2017 Euros; QALY, quality-adjusted life year; WTP, willingness to pay.
Figure 3 Cost-effectiveness acceptability curve.